'A treatment-risk paradox where patients become less likely to receive appropriate treatment with advancing age has been observed in the secondary prevention of cardiovascular disease (CVD). This is particularly apparent for cholesterol-lowering treatment with one study showing the likelihood of statin treatment was 6% lower with each year increase in age. However, it is not clear if such a paradox exists in primary prevention and a recent UK study published in the BMJ addresses this issue...'